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in Women
Conﬁrming Translational Science or More Confounded
Clinical Research?*Joseph E. Bavaria, MD,y Jay Giri, MD, MPHzI n both animals and humans, differences havebeen noted in left ventricular remodelingbetween sexes when faced with the chronic
pressure overload of aortic valve stenosis (AS) (1,2).
Women, on average, develop thicker ventricles with
greater preservation of ejection fraction and less
ﬁbrosis than male counterparts when faced with AS
(2,3). Hence, despite being labeled uniformly as
“severe AS patients” when presenting for aortic valve
replacement (AVR), women and men may demon-
strate markedly different phenotypes when con-
sidering the complete physiological picture of
ventricular performance and valvuloarterial imped-
ance. Initial studies suggest that left ventricular
mass regression occurs more frequently and rapidly
in women after AVR, allowing them to normalize ven-
tricular biomechanics to a greater degree than
men (4). Taken in sum, these translational data lead
to the intriguing possibility that women may exhibit
a differential and positive treatment response to
AVR for AS. To date, clinical outcomes data address-
ing this question have been mixed (5–7).SEE PAGE 221
*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yCardiovascular Surgery Division, University of Pennsylvania
Perelman School of Medicine, Philadelphia, Pennsylvania; and the
zCardiovascular Medicine Division, University of Pennsylvania Perelman
School of Medicine, Philadelphia, Pennsylvania. Dr. Bavaria was a
coprincipal investigator on the PARTNER trials, sponsored by Edwards
Lifesciences and the SURTAVI trial sponsored by Medtronic, Inc.; and
was on the steering committee for the REPRISE III Trial, sponsored by
Boston Scientiﬁc. Dr. Giri was a subinvestigator on the PARTNER trials
and the SURTAVI trial.In this issue of the Journal, O’Connor et al. (8) add
to the relatively sparse existing published data on this
topic by comparing outcomes between the sexes in
high and extreme surgical risk patients that under-
went transcatheter aortic valve replacement (TAVR).
The authors should be congratulated for working
collaboratively to share the data necessary to perform
this analysis. In this era of big data with standardized
outcome assessments and the ability for carefully
planned post-hoc statistical analysis, such observa-
tional efforts are a vital window into broad practice
patterns and outcomes. As President Harry S. Truman
noted, “It is amazing what you can accomplish if you
don’t care who gets the credit” (9).
As opposed to a traditional meta-analysis that
relies only on published data to compute and
combine effect sizes, the current investigation pools
patient-level data from the original study datasets to
create a new, larger database for de novo analysis.
In situations like the present study, where the
criteria for subject inclusion in the source trials do
not exhibit much heterogeneity, this design may
allow for more granular assessment of potential
predictors of post-TAVR outcomes than that of a
traditional meta-analysis. Despite these methodo-
logical strengths, the study design remains observa-
tional, and the analysis is potentially victim to
treatment-selection bias.
The authors note several key ﬁndings. As has been
seen in previous research, women were more likely to
experience vascular complications and less likely to
be left with post-procedural aortic insufﬁciency
(10,11). The most important ﬁndings, though, related
to mortality. In comparison to men, women experi-
enced similar 30-day mortality rates but had sig-
niﬁcantly lower 1- and 2-year mortality after TAVR.
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230Do these ﬁndings reﬂect a true differential treatment
response to TAVR in women, conﬁrming the theo-
rized pathophysiological mechanisms noted in the
preceding text? Or are the present ﬁndings actually a
result of comparing a lower-risk cohort of women
with a higher-risk cohort of men?
In order to address this, we must ask ourselves
why lower-risk women may have been systemati-
cally chosen for inclusion in these seminal trials and
registries of high- and extreme-risk TAVR. An
answer lies in the inclusion criteria of the studies,
which relied heavily upon quantitative Society of
Thoracic Surgeons or EuroScore risk scores that were
designed to predict 30-day mortality after surgical
aortic valve replacement (SAVR). The risk models
were used during surgical evaluations and heart
team meetings as a quantitative metric to charac-
terize patients as high risk for SAVR, thus justifying
utilization of TAVR. The risk models code female sex
as an independent risk factor for mortality. Thus,
other factors being equal, women have higher Soci-
ety of Thoracic Surgeons and EuroScore risk scores
for 30-day mortality after SAVR than their male
counterparts. And, in fact, these predictive scores
proved fairly accurate in distinguishing early oper-
ative risk among the male and female cohorts when
applied to TAVR patients in the present study (8).
Predicted risks between the cohorts were similar,
and the actual 30-day mortalities were nearly iden-
tical. The implication is that women, despite
entering the TAVR procedure with signiﬁcantly
fewer comorbidities than their male counterparts,
sustained a similar periprocedural mortality rate as
was predicted by pre-operative SAVR risk models.
However, notable differences over longer-term
follow-up were seen, with women achieving higher
survival rates at 1 year and mortality curves
continuing to diverge to 2 years, with women
increasing their survival advantage over time. From a
valvular standpoint, it is well known that para-
valvular aortic insufﬁciency was the “Achilles’ heel”
of the early-generation TAVR technology used in
these datasets. Aortic insufﬁciency was less common
in women because of their smaller average annular
sizes and the resultant more aggressive TAVR bio-
prosthesis oversizing. Importantly, the authors
controlled for differences in moderate or greater
aortic insufﬁciency in their Cox proportional hazard
model, ideally mitigating some of its inﬂuence on the
observed results (8). However, mild aortic insufﬁ-
ciency, which was also more common in men in these
studies, represents a confounder, given its known
relationship with late mortality (12). Nevertheless,
the differences in rates of aortic insufﬁciency do notseem nearly great enough to account for such signif-
icant observed mortality differences.
Apart from the issue of paravalvular aortic
insufﬁciency, TAVR devices have proven to be quite
durable technically, with late death rates largely
attributed to the high burdens of comorbid condi-
tions, both cardiac and noncardiac, present in those
treated with the procedure (13,14). In the current
study (8), observed comorbidities were far greater
in men, and attempts were made to control for
these measured covariates. However, it is a distinct
possibility that this widespread and signiﬁcantly
higher general burden of comorbid illness among
men served as a marker for other unmeasured
confounding conditions that placed them at higher
risk of late death post-TAVR. The initial selection of
patients for TAVR was based upon scoring systems
used to stratify patients into high-risk cohorts
that were designed to predict only 30-day opera-
tive results and were not TAVR speciﬁc. Thus,
the late mortality beneﬁts seen in women may
have emerged as a result of their relative absence
of comorbid conditions, as opposed to a differ-
entially positive response to TAVR over long-term
follow-up.
We cannot be sure that the multivariable model
used in the current analysis was inadequate to
control for baseline differences in risk between men
and women. However, studies such as this raise
important methodological issues for the conduct of
future observational research with large prospective
datasets. One way to more deﬁnitively assess
for unmeasured confounding in observational
studies is through the analysis of falsiﬁcation end-
points (15). A falsiﬁcation endpoint is an outcome
highly unlikely to be inﬂuenced by the studied
intervention that can be compared between
matched groups to verify true absence of con-
founding, similar to a negative control experiment
in a basic science investigation.
For prospective TAVR registries, consideration
should be given to pre-specifying several falsiﬁcation
endpoints as part of data collection efforts. Examples
of potential falsiﬁcation endpoints for an analysis
of late mortality after TAVR include incident hip
fracture or urosepsis. Both are conditions that are
unlikely to be associated with the initial procedure,
but could raise concerns about unmeasured con-
founding if they were found to be unbalanced in
purportedly “adjusted” cohorts during post-hoc
observational comparative analyses.
Clearly, characterizing the inﬂuence of sex upon
TAVR outcomes is not straightforward. Sex is an
immutable trait, hence treatment-selection bias
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such, the best way to determine effects of sex on
TAVR outcomes will be to develop a TAVR-speciﬁc
long-term mortality risk model utilizing a truly
unselected patient population. It would be inter-
esting to see whether female sex emerges as a
“protective” factor in such a model. Given the
rapid promulgation of TAVR into lower-risk cohorts
and the careful prospective data accumulationtaking place in multiple national registries, such a
goal may be achievable in the not-too-distant
future.
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